Eagle Health Investments LP Purchases Shares of 884,121 Ultragenyx Pharmaceutical Inc. $RARE

Eagle Health Investments LP bought a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the 1st quarter, Holdings Channel.com reports. The firm bought 884,121 shares of the biopharmaceutical company’s stock, valued at approximately $18,522,000. Ultragenyx Pharmaceutical comprises 3.2% of Eagle Health Investments LP’s holdings, making the stock its 13th biggest position.

Several other institutional investors and hedge funds have also bought and sold shares of RARE. Parallel Advisors LLC lifted its position in Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,440 shares during the last quarter. Leonteq Securities AG boosted its stake in shares of Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,333 shares during the period. Danske Bank A S bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth approximately $39,000. Aster Capital Management DIFC Ltd bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter worth approximately $56,000. Finally, Smartleaf Asset Management LLC increased its stake in shares of Ultragenyx Pharmaceutical by 43.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,489 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 751 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Stock Down 0.0%

Shares of Ultragenyx Pharmaceutical stock opened at $26.89 on Tuesday. The business has a 50 day moving average of $27.50 and a 200 day moving average of $24.68. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $39.89. The company has a market cap of $2.65 billion, a PE ratio of -4.40 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business’s revenue was down 2.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.57) EPS. On average, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on RARE shares. Guggenheim lowered their price target on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a report on Friday, May 8th. Wedbush decreased their price objective on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Royal Bank Of Canada upped their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Finally, Wells Fargo & Company raised their target price on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $58.41.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Shehnaaz Suliman sold 5,740 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $25.12, for a total transaction of $144,188.80. Following the transaction, the director owned 27,951 shares in the company, valued at $702,129.12. The trade was a 17.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Howard Horn sold 4,653 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the transaction, the chief financial officer directly owned 105,689 shares of the company’s stock, valued at approximately $2,512,227.53. The trade was a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 19,319 shares of company stock valued at $476,837. 5.20% of the stock is currently owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.